ADDF Impact

Celebrating Alzheimer’s Science and Scientists at the 2022 ADDF Goodes Prize Luncheon

Five previous winners of the prestigious Melvin R. Goodes Prize came together in New York City recently to honor this year’s winner, Miranda E. Orr, PhD, Assistant Professor of Gerontology and Geriatric Medicine at the Wake Forest University School of Medicine, and to discuss how their research is working toward the same goal – to conquer Alzheimer’s.

Protecting Brain Health

Can Lifestyle Interventions Combined with a Diabetes Drug Prevent Cognitive Decline?

Alzheimer’s Drug Discovery Foundation Funds Second Phase of Global Alzheimer’s Prevention FINGER TRIAL

2021 and Beyond: Research Forges Beyond Aduhelm with More Drug Approvals Expected from Diverse and Promising Pipeline

First new Alzheimer’s treatment approved in 17 years, two more get breakthrough designation for FDA review

The FDA approved aducanumab (Aduhelm®), an antibody that clears amyloid plaques from the brain, in June. 

Developing Drugs

A Conversation with Our ADDF-Harrington Scholars: Studying Drug Candidates to Restore Brain Function in Alzheimer’s Patients

Earlier this year, two outstanding researchers, Paul Fish, Ph.D., and Paul Worley, M.D., were selected by the ADDF and Harrington Discovery Institute to receive ADDF-Harrington Scholar Awards.

CTAD 2021 Reflects Promising Movement in Alzheimer’s Research

The theme of the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference asked a question: Therapeutic Trials in AD: A New Hope for 2022?